<DOC>
	<DOCNO>NCT02304393</DOCNO>
	<brief_summary>This open-label , multicenter study design assess safety , pharmacokinetics , pharmacodynamics activity RO7009789 administer combination atezolizumab ( ATZ ) participant metastatic locally advanced solid tumor . The study conduct three Parts ( I , II , III ) , part I divide Parts IA IB . All participant follow survival death loss follow-up last visit withdrawal consent .</brief_summary>
	<brief_title>A Study RO7009789 Combination With Atezolizumab Participants With Locally Advanced Metastatic Solid Tumors</brief_title>
	<detailed_description />
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Histologically confirm diagnosis locally advance and/or metastatic solid tumor , amenable standard therapy Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 Life expectancy great equal ( &gt; /= ) 16 week Adequate hematologic end organ function Measurable disease per RECIST version 1.1 Ability comply collection tumor biopsy ; tumor must accessible biopsy Agreement use effective method contraception per protocol requirement ; female participant childbearing potential must negative pregnancy test ( urine/serum ) within 7 day prior first study drug administration If one follow laboratory result obtain within 14 day prior first study treatment ( Cycle 1 Day 1 ) : soluble interleukin 2 receptor ( sCD25 ) &gt; 2 Ã— upper limit normal ( ULN ) ; Serum ferritin &gt; 1000 nanogram per milliliter ( ng/mL ) Any approved anticancer therapy include chemotherapy , hormonal therapy , radiotherapy within 2 week prior first dose study treatment ; follow , however , allow : Palliative radiotherapy bone metastases &lt; /= 2 week prior Cycle 1 Day 1 Adverse event prior anticancer therapy resolve Grade &lt; /= 1 except grade alopecia &lt; /= Grade 2 peripheral neuropathy Bisphosphonate therapy symptomatic hypercalcemia . Use bisphosphonate therapy reason ( example : bone metastasis osteoporosis ) allow Uncontrolled pleural effusion , pericardial effusion , ascites require recurrent drainage procedure ( one monthly frequently ) . Participants indwell catheter allow Known clinically significant liver disease include active viral , alcoholic , hepatitis , cirrhosis , fatty liver , inherit liver disease History ( within previous year ) congestive heart failure , stroke , arrhythmia , myocardial infarction History peripheral venous thrombosis thromboembolic event ( within 12 month prior Cycle 1 Day 1 ) Significant cardio cerebrovascular disease within 6 month prior Cycle 1 Day 1 Known hereditary acquire coagulopathies Clinically meaningful proteinuria Requiring dialysis ( peritoneal hemodialysis ) Known primary central nervous system ( CNS ) malignancy symptomatic untreated CNS metastasis : participant asymptomatictreated CNS metastasis may enrol consultation Medical Monitor , provide meet follow criterion : Radiographic demonstration improvement upon completion CNSdirected therapy evidence interim progression completion CNSdirected therapy screen radiographic study No stereotactic radiation wholebrain radiation within 28 day prior Cycle 1 Day 1 Pregnancy , lactation , breastfeed Allergy hypersensitivity component RO7009789 formulation component atezolizumab formulation History autoimmune disease ( participant history autoimmune hypothyroidism stable dose thyroid replacement hormone may eligible ; participant control Type 1 diabetes mellitus stable insulin regimen may eligible study ) History idiopathic pulmonary fibrosis , pneumonitis ( exclude infectious diseaseinduced ) , organize pneumonia , evidence active pneumonitis . History radiation pneumonitis radiation field ( fibrosis ) permit Participants human immunodeficiency virus ( HIV ) infection , active hepatitis B ( chronic acute ) , hepatitis C infection Active tuberculosis Severe infection within 4 week prior Cycle 1 Day 1 Signs symptom infection within 2 week prior Cycle 1 Day 1 Received oral IV antibiotic within 2 week prior Cycle 1 Day 1 Major surgical procedure within 28 day prior Cycle 1 Day 1 anticipation need major surgical procedure course study Administration live , attenuated vaccine within 4 week Cycle 1 Day 1 anticipation live attenuated vaccine require study Malignancies disease study within 3 year prior Cycle 1 Day 1 exception negligible risk metastasis death expect curative outcome Prior treatment anticytotoxic Tlymphocyte associate protein 4 ( antiCTLA4 ) , antiprogrammed death1 ( antiPD1 ) , antiprogrammed death ligand1 ( antiPDL1 ) therapeutic antibody Previous treatment compound target cluster differentiation 40 ( CD40 ) ( like Chi Lob 7/4 ADC1013 ) Treatment systemic immunostimulatory agent ( include limit interferon ( IFN ) gamma , Interleukin2 ( IL2 ) within 4 week 5 time halflife drug , whichever short , prior Cycle 1 Day 1 Treatment investigational agent within 4 week prior Cycle 1 Day 1 ( within 5 time halflife investigational product , whichever long ) Concomitant treatment anticoagulant ( example : Coumadin , heparin ) except low dose molecular weight heparin prophylactic purpose Treatment systemic immunosuppressive medication ( include limit prednisone , cyclophosphamide , azathioprine , methotrexate , thalidomide , antitumor necrosis factor ( TNF ) agent within 2 week prior Cycle 1 Day 1 Participants receive acute , lowdose , systemic immunosuppressant medication ( example : onetime dose dexamethasone nausea ) may enrol study discussion approval Medical Monitor . The use inhale corticosteroid use mineralocorticoid ( example : fludrocortisone ) participant orthostatic hypotension adrenocortical insufficiency allow History severe allergic , anaphylactic , hypersensitivity reaction chimeric humanize antibody fusion proteins Participants prior allogeneic bone marrow transplantation prior solid organ transplantation Any disease , metabolic dysfunction , physical examination finding , clinical laboratory find give reasonable suspicion disease condition contraindicate use investigational drug may affect interpretation result render participant high risk treatment complication</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
</DOC>